https://www.prnewswire.com/news-releases/antengene-enters-into-a-global-clinical-collaboration-with-msd-to-evaluate-atg-037-cd73-inhibitor-in-combination-with-keytruda-pembrolizumab-301709910.html
0
0
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab) - PR Newswire
12/27/22 at 12:30am
Organization
PRNewswire
Authors
Details
40 words
Summarize
Pharmaceuticals & Biotech Business & Industrial Antengene Corporation Limited Antengene Enters Global Clinical Collaboration ATG-037 Keytruda CD73 Inhibitor PRNewswire HKEX 6996.HK
/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to...
Create an account or login to join the discussion